# Step down of asthma biologics in real-world practice settings

> **NIH NIH R21** · MAYO CLINIC ARIZONA · 2020 · $21,370

## Abstract

Our overall goal is to identify risk factors in people with asthma for being hospitalized for COVID-19. Our team
is uniquely positioned to quickly analyze pre-existing data that includes risk factors likely to be relevant for
people with asthma who are hospitalized for COVID-19. Our team has used a claims data set that includes
200+ million people residing in the US in multiple studies in people with asthma called OptumLabs Database
Warehouse (OLDW).
We hypothesize that there are behavior, health care delivery, and patient demographic factors associated with
hospitalization for COVID-19 in people with asthma. To test this hypothesis, we will analyze pre-existing data
from OLDW, testing the following independent variables: age, sex, race-ethnicity, smoking, comorbid chronic
diseases, geographic region, rural/urban residence, access to provider care (traditional and telehealth),
medication-filling behavior, and types of asthma medications filled.

## Key facts

- **NIH application ID:** 10148448
- **Project number:** 3R21HL140287-02S1
- **Recipient organization:** MAYO CLINIC ARIZONA
- **Principal Investigator:** Matthew A Rank
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $21,370
- **Award type:** 3
- **Project period:** 2020-09-01 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10148448

## Citation

> US National Institutes of Health, RePORTER application 10148448, Step down of asthma biologics in real-world practice settings (3R21HL140287-02S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10148448. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*